What is MNKD stock price today?

MNKD (MannKind Corp) stock is trading at $5.49 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is MNKD stock going up or down today?

MNKD stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy MNKD stock now?

The decision to buy MNKD depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is MNKD a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for MNKD based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is MNKD stock overvalued or undervalued?

MNKD currently trades at a P/E ratio of 50.70, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if MNKD is fairly priced.

What is MNKD's P/E ratio?

MNKD has a price-to-earnings (P/E) ratio of 50.70, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is MNKD's market cap?

MNKD (MannKind Corp) has a market capitalization of $1.56 billion, making it a small-cap stock.

What is MNKD's price to book ratio?

Price-to-book ratio for MNKD is available on our dashboard along with other valuation metrics.

Does MNKD pay dividends?

MNKD does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is MNKD's dividend yield?

MNKD does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is MNKD stock a good long-term investment?

MNKD's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is MNKD's revenue growth rate?

MNKD has shown revenue growth of 0.2% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, MNKD is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in MNKD?

Key risks for MNKD include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does MNKD compare to its competitors?

Compare MNKD to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize MNKD's performance and positioning.

What is MNKD's stock price target for 2026?

Our AI model provides price targets for MNKD based on fundamental analysis: Bull case $7.14 (+30%), Base case $6.31 (+15%), Bear case $4.94 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about MNKD?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for MNKD. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is MNKD's next earnings report?

MNKD reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

MNKD - MannKind Corp

NYSE * Healthcare * Biotechnology

$5.49

+$0.28 (+5.37%)

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MNKD Key Statistics

Market Cap

$1.56B

P/E Ratio

50.70

EPS

$0.10

Revenue Growth

+0.2%

Profit Margin

0.1%

Employees

403

How MNKD Compares to Peers

MNKD trades at a premium valuation vs peers (highest P/E)

MNKD has the fastest revenue growth among competitors

MNKD is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
MNKD(This stock)	$1.56B	50.7	0%	0.1%	-
AMGNAmgen Inc	$178.24B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.03B	19.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.35B	31.2	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.77B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

MannKind Corp Company Information

Headquarters: 1 Casper Street, Danbury, CT, United States, 06810, undefined
Website: www.mannkindcorp.com
Sector: Healthcare
Industry: Biotechnology

MNKD - MannKind Corp

About MannKind Corp

MNKD Key Statistics

How MNKD Compares to Peers

MannKind Corp Company Information

MNKD Lician Score

MNKD Financial Snowflake

Upcoming Events for MNKD